Assignee
LEK PHARMACEUTICALS
SI57 patents
Top patents by PatentIndex Score
US6740775B1May 25, 2004
Crystalline sodium salt of pravastatin
LEK PHARMACEUTICALS15 citations92
US6613916B2Sep 2, 2003
Process for the preparation of amorphous atorvastatin
LEK PHARMACEUTICALS30 citations92
US6583295B1Jun 24, 2003
Salts of HMG-CoA reductase inhibitors
LEK PHARMACEUTICALS32 citations92
US7485322B2Feb 3, 2009
Modified release pharmaceutical composition
LEK PHARMACEUTICALS29 citations91
US6680341B1Jan 20, 2004
Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor
LEK PHARMACEUTICALS19 citations91
US6531507B1Mar 11, 2003
Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
LEK PHARMACEUTICALS47 citations91
US6695969B1Feb 24, 2004
Process for obtaining HMG-CoA reductase inhibitors of high purity
LEK PHARMACEUTICALS18 citations88
US8053444B2Nov 8, 2011
Sirolimus formulation
LEK PHARMACEUTICALS20 citations87
US7030151B2Apr 18, 2006
Atorvastatin calcium in a pharmaceutical form composition thereof and pharmaceutical formulation comprising atorvastatin calcium
LEK PHARMACEUTICALS39 citations83
US6891047B2May 10, 2005
Process for the preparation of amorphous atorvastatin
LEK PHARMACEUTICALS14 citations83
US6806290B2Oct 19, 2004
Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
LEK PHARMACEUTICALS14 citations82
US7906109B2Mar 15, 2011
Pharmaceutical composition comprising an active principal and sulphobetaine
LEK PHARMACEUTICALS7 citations78
US7655437B2Feb 2, 2010
Synthetic gene coding for human granulocyte-colony stimulating factor for the expression in E. coli
LEK PHARMACEUTICALS9 citations74
US6838566B2Jan 4, 2005
Salts of HMG-CoA reductase inhibitors
LEK PHARMACEUTICALS10 citations73
US6984399B2Jan 10, 2006
Solid pharmaceutical formulation containing lovastatin and simvastatin respectively, and its preparation
LEK PHARMACEUTICALS5 citations68
US6696086B1Feb 24, 2004
Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
LEK PHARMACEUTICALS5 citations68
US9732053B2Aug 15, 2017
1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
LEK PHARMACEUTICALS2 citations66
US6825015B1Nov 30, 2004
Process for the obtaining of HMG-COA reductase inhibitors of high purity
LEK PHARMACEUTICALS7 citations66
US9493409B2Nov 15, 2016
Process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
LEK PHARMACEUTICALS3 citations65
US8354530B2Jan 15, 2013
Process for the synthesis of rosuvastatin calcium
LEK PHARMACEUTICALS4 citations57
US7585496B2Sep 8, 2009
Stable pharmaceutical composition granulocyte-colony stimulating factor
LEK PHARMACEUTICALS2 citations56
US9284320B2Mar 15, 2016
Ticagrelor adducts with divalent metal salts
LEK PHARMACEUTICALS2 citations55
US9388188B2Jul 12, 2016
Synthetic route for the preparation of β-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha ]pyrazin-7-yl compounds
LEK PHARMACEUTICALS2 citations53
US7534870B2May 19, 2009
Stable pharmaceutical composition comprising erythropoietin
LEK PHARMACEUTICALS3 citations51
US10323056B2Jun 18, 2019
Crystalline hydrates of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
LEK PHARMACEUTICALS0 citations49
US7923570B2Apr 12, 2011
Process for the preparation of crystalline perindopril
LEK PHARMACEUTICALS0 citations49
US7671215B2Mar 2, 2010
Process for the preparation of compounds having an ace inhibitory action
LEK PHARMACEUTICALS1 citations48
US7560474B2Jul 14, 2009
Derivatives of pyridilethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, process for their preparation and pharmaceutical compositions containing them
LEK PHARMACEUTICALS2 citations48
US7141602B2Nov 28, 2006
Process for obtaining HMG-CoA reductase inhibitors of high purity
LEK PHARMACEUTICALS1 citations48
US6509479B1Jan 21, 2003
Process for the removal of a silyloxy protecting group from 4-silyloxy-tetrahydro-pyran-2-ones
LEK PHARMACEUTICALS1 citations48
US8367848B2Feb 5, 2013
Process for the preparation of amorphous calcium salt of atorvastatin
LEK PHARMACEUTICALS0 citations47
US9907757B2Mar 6, 2018
Coated particles and pharmaceutical dosage forms
LEK PHARMACEUTICALS0 citations45
US9944599B2Apr 17, 2018
Processes for the preparation of beta-aminosulfone compounds
LEK PHARMACEUTICALS1 citations43
US9622976B2Apr 18, 2017
Pharmaceutical composition
LEK PHARMACEUTICALS0 citations43
US9453030B2Sep 27, 2016
Oxidative degradation products of atrovastatin calcium
LEK PHARMACEUTICALS0 citations43
US8362259B2Jan 29, 2013
Process for the preparation of esomeprazole magnesium in a stable form
LEK PHARMACEUTICALS0 citations43
US8044086B2Oct 25, 2011
Oxidative degradation products of atorvastatin calcium
LEK PHARMACEUTICALS0 citations43
US7538246B2May 26, 2009
Synthesis of optically pure(r)-5-(2-amynopropyl)-2-methoxybenzenesulphonamide
LEK PHARMACEUTICALS0 citations43
US7968727B2Jun 28, 2011
Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists
LEK PHARMACEUTICALS0 citations42
US7632843B2Dec 15, 2009
Treatment of psychostimulant addiction
LEK PHARMACEUTICALS0 citations42
US7271269B2Sep 18, 2007
Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
LEK PHARMACEUTICALS1 citations41
US7553857B2Jun 30, 2009
S-omeprazole magnesium
LEK PHARMACEUTICALS0 citations40
US10196601B2Feb 5, 2019
Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides
LEK PHARMACEUTICALS0 citations39
US7153970B2Dec 26, 2006
High purity amlodipine benzenesulfonate and a process for its preparation
LEK PHARMACEUTICALS0 citations39
US10913984B2Feb 9, 2021
Predicting genetically stable recombinant protein production in early cell line development
LEK PHARMACEUTICALS0 citations38
US10189860B2Jan 29, 2019
Hydrates of dolutegravir sodium
LEK PHARMACEUTICALS0 citations37
US9562082B2Feb 7, 2017
Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
LEK PHARMACEUTICALS0 citations37
US9428562B2Aug 30, 2016
Production of glycoproteins with low N-glycolylneuraminic acid (NEU5GC) content
LEK PHARMACEUTICALS0 citations37
US7875723B2Jan 25, 2011
S-omeprazole magnesium
LEK PHARMACEUTICALS0 citations37
US7285547B2Oct 23, 2007
Amidinophenylalanine derivatives as thrombin inhibitors
LEK PHARMACEUTICALS0 citations37
Showing the top 50 of 57 patents by PatentIndex Score.